Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Dec

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Addition of Neoadjuvant LuPSMA PNT2002 to SBRT in Oligorecurrent Prostate Cancer

Preliminary Activity of LuPSMA-IT Plus Ra-223 in Metastatic Castration-Resistant Prostate Cancer With Bone Metastasis

Image-Only AI Model Outperforms Breast Density for 5-Year Breast Cancer Risk Stratification

Tisagenlecleucel in Relapsed or Refractory Large B-Cell Lymphoma

Retrospective Review Shows Persistent Breast Cancer Burden in Younger Women